Vertex Pharmaceuticals Inc. shares rose after the biotech company said its drug to treat a kidney disorder met its goal in a ...

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

March 9 (Reuters) - Vertex Pharmaceuticals said on Monday that its experimental kidney disease drug met the main goal of a ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney ...

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

Investing.com -- Vertex Pharmaceuticals (NASDAQ:VRTX) shares rose 6% to $488.52 in premarket trading Thursday after the company reported successful results from a late-stage trial of its kidney ...

Vertex Pharmaceuticals shares surged Tuesday after the company posted promising results from a clinical trial of a drug to treat kidney disease.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial ...

Vertex delivers tax technology software and SaaS solutions to corporations seeking streamlined compliance and integration capabilities.